• Solid Oral Dosage Forms
  • Sustained Release (ER/SR/DR) Formulations
  • Poorly Soluble Drugs
  • Unstable Molecules
  • Potent Compounds
  • Bioavailability Enhancement
  • Technically Challenging Products


i3 Pharmaceuticals has acquired a 150,000 square feet facility in Warminster, PA. i3 Pharmaceuticals has occupied 75,000 square feet of the facility and built state of the art research and analytical laboratories, pilot and commercial manufacturing plants and warehouses and has an additional 75,000 square feet of space available for expansion.